These results suggest that MICAL1 could represent a promising therapeutic target for pathologies characterized by VWF hyperactivation, such as in patients who have undergone transcatheter aortic valve implantation (TAVI) or those with type 2B von Willebrand disease. Here, MICAL1 is linked to Von Willebrand disease.